Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.51
FLDM's Cash to Debt is ranked lower than
75% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. FLDM: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
FLDM' s 10-Year Cash to Debt Range
Min: 0.32  Med: 5.27 Max: No Debt
Current: 0.51
Equity to Asset 0.34
FLDM's Equity to Asset is ranked lower than
82% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. FLDM: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
FLDM' s 10-Year Equity to Asset Range
Min: -7.63  Med: 0.72 Max: 0.89
Current: 0.34
-7.63
0.89
F-Score: 4
Z-Score: -0.23
M-Score: -2.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -43.50
FLDM's Operating margin (%) is ranked lower than
67% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. FLDM: -43.50 )
Ranked among companies with meaningful Operating margin (%) only.
FLDM' s 10-Year Operating margin (%) Range
Min: -338.59  Med: -44.51 Max: -26.2
Current: -43.5
-338.59
-26.2
Net-margin (%) -47.18
FLDM's Net-margin (%) is ranked lower than
68% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. FLDM: -47.18 )
Ranked among companies with meaningful Net-margin (%) only.
FLDM' s 10-Year Net-margin (%) Range
Min: -368.13  Med: -52.42 Max: -23.22
Current: -47.18
-368.13
-23.22
ROE (%) -37.65
FLDM's ROE (%) is ranked lower than
68% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. FLDM: -37.65 )
Ranked among companies with meaningful ROE (%) only.
FLDM' s 10-Year ROE (%) Range
Min: -42.81  Med: -24.15 Max: -16.77
Current: -37.65
-42.81
-16.77
ROA (%) -13.84
FLDM's ROA (%) is ranked lower than
59% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. FLDM: -13.84 )
Ranked among companies with meaningful ROA (%) only.
FLDM' s 10-Year ROA (%) Range
Min: -67.71  Med: -49.47 Max: -14.33
Current: -13.84
-67.71
-14.33
ROC (Joel Greenblatt) (%) -216.36
FLDM's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. FLDM: -216.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -805.14  Med: -231.92 Max: -138.28
Current: -216.36
-805.14
-138.28
Revenue Growth (3Y)(%) 20.40
FLDM's Revenue Growth (3Y)(%) is ranked higher than
89% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. FLDM: 20.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLDM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -45.80 Max: 20.4
Current: 20.4
0
20.4
EBITDA Growth (3Y)(%) 11.60
FLDM's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. FLDM: 11.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
FLDM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -58.80 Max: 11.6
Current: 11.6
0
11.6
EPS Growth (3Y)(%) 1.60
FLDM's EPS Growth (3Y)(%) is ranked higher than
51% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. FLDM: 1.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
FLDM' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -57.80 Max: 1.6
Current: 1.6
0
1.6
» FLDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

FLDM Guru Trades in Q3 2014

RS Investment Management 536,748 sh (+2.31%)
PRIMECAP Management 3,689,632 sh (+1.05%)
Jim Simons Sold Out
» More
Q4 2014

FLDM Guru Trades in Q4 2014

RS Investment Management 793,478 sh (+47.83%)
PRIMECAP Management 3,726,832 sh (+1.01%)
» More
Q1 2015

FLDM Guru Trades in Q1 2015

RS Investment Management 909,448 sh (+14.62%)
PRIMECAP Management 3,725,832 sh (-0.03%)
» More
Q2 2015

FLDM Guru Trades in Q2 2015

Steven Cohen 63,400 sh (New)
PRIMECAP Management 4,069,132 sh (+9.21%)
RS Investment Management Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.50
FLDM's P/B is ranked higher than
61% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. FLDM: 2.50 )
Ranked among companies with meaningful P/B only.
FLDM' s 10-Year P/B Range
Min: 2.5  Med: 5.05 Max: 12.53
Current: 2.5
2.5
12.53
P/S 2.78
FLDM's P/S is ranked higher than
52% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. FLDM: 2.78 )
Ranked among companies with meaningful P/S only.
FLDM' s 10-Year P/S Range
Min: 0.94  Med: 6.89 Max: 16.73
Current: 2.78
0.94
16.73
Current Ratio 4.96
FLDM's Current Ratio is ranked higher than
76% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. FLDM: 4.96 )
Ranked among companies with meaningful Current Ratio only.
FLDM' s 10-Year Current Ratio Range
Min: 1.13  Med: 4.77 Max: 8.73
Current: 4.96
1.13
8.73
Quick Ratio 4.31
FLDM's Quick Ratio is ranked higher than
76% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. FLDM: 4.31 )
Ranked among companies with meaningful Quick Ratio only.
FLDM' s 10-Year Quick Ratio Range
Min: 0.86  Med: 4.27 Max: 8.11
Current: 4.31
0.86
8.11
Days Inventory 133.39
FLDM's Days Inventory is ranked lower than
75% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. FLDM: 133.39 )
Ranked among companies with meaningful Days Inventory only.
FLDM' s 10-Year Days Inventory Range
Min: 102.81  Med: 149.83 Max: 443.32
Current: 133.39
102.81
443.32
Days Sales Outstanding 67.12
FLDM's Days Sales Outstanding is ranked lower than
53% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. FLDM: 67.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLDM' s 10-Year Days Sales Outstanding Range
Min: 54.11  Med: 89.97 Max: 124.82
Current: 67.12
54.11
124.82

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
FLDM's Price/Median PS Value is ranked higher than
87% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. FLDM: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
FLDM' s 10-Year Price/Median PS Value Range
Min: 0.14  Med: 1.03 Max: 2.01
Current: 0.4
0.14
2.01
Earnings Yield (Greenblatt) (%) -12.30
FLDM's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. FLDM: -12.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLDM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -12.39  Med: 0.00 Max: 0
Current: -12.3
-12.39
0

Analyst Estimate

Dec15 Dec16 Dec17
EPS($) -2.20 -1.95 -1.50
EPS without NRI($) -2.20 -1.95 -1.50

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:FLB.Germany,
Fluidigm Corp is a Delaware Corporation formed in May, 1999. The Company develops, manufacture, and market microfluidic systems to academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology (Ag-Bio) companies in growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing. These systems are designed to simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits (IFCs), assays, and reagents. The Company's primary area of development within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including 18 different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to the academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 920 systems to customers in over 35 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufactures IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with companies such as Affymetrix, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Life Technologies Corporation (now part of Thermo Fisher Scientific), LGC Limited, Luminex Corporation, NanoString Technologies, Inc., PerkinElmer, Inc. (through its acquisition of Caliper Life Sciences, Inc.), RainDance Technologies, Inc., Roche Applied Science (a division of Roche Diagnostics Corporation), Sequenom, Inc., Thermo Fisher Scientific Inc., and WaferGen Bio-Systems, Inc.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK